CHMP recommends nine new drugs, rejects one
Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.
by ELIZABETH MØNSTED JOHANSEN, translated by Daniel Pedersen
Pfizer's medicine candidate tanezumab is the only new medicine that the European Committee for Medicinal Products for Human Use (CMPH) is refusing to approve. This is clear from the highlights publicized after the committee's September meeting.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA begins assessment of Pfizer booster application
For subscribers
